Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Laboratory for Pathology, Dordrecht, The Netherlands.
Mod Pathol. 2020 Feb;33(2):196-205. doi: 10.1038/s41379-019-0331-8. Epub 2019 Aug 2.
Ductal carcinoma in situ of the breast includes several subtypes with a divergent biological behavior. Data regarding the composition of ductal carcinoma in situ-associated immune cells and their potential role in progression is limited. We studied ductal carcinoma in situ-associated immune response by characterizing immune cell subsets according to ductal carcinoma in situ subtypes. Ductal carcinoma in situ-associated tumor infiltrating lymphocyte (TIL) density was evaluated based on hematoxylin and eosin (H&E)-stained sections from 473 patients. Cases were subtyped based on ER, PR, and HER2. Patients were categorized as TIL-high or low. Ductal carcinoma in situ-associated immune cells of TIL-high cases were immunostained on whole slides with CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 and SP263). In total, 131/473 patients (28.0%) were considered as TIL-high. The percentage of TIL-high cases was significantly higher in HER2+ and triple-negative ductal carcinoma in situ (P < 0.0001). Overall, no statistical difference in immune cell composition according to subtypes was found. However, individual subtype comparison showed that ER+ HER2+ cases had a significantly higher proportion of CD8+ T cells compared with triple-negative cases (P = 0.047). In TIL-high cases, PD-L1-SP142 expression on tumor cells was associated with subtype (P = 0.037); the lowest number of positive cases was observed in the HER2+ subtype (independent of ER). However, in TIL-high ductal carcinoma in situ, PD-L1 expression by both clones was limited. In conclusion, high numbers of TILs are predominantly observed in HER+ and triple negative ductal carcinoma in situ. The ER+ HER2+ subtype seems to attract a higher proportion of CD8+ T cells compared with the triple negative subtype. Among TIL-high cases, the HER2+ subgroup had the lowest PD-L1-SP142 expression on tumor cells. This suggests a more pronounced antitumor immunity in HER2+ ductal carcinoma in situ, which could play a role in its biological behavior.
乳腺导管原位癌包括几种具有不同生物学行为的亚型。关于与导管原位癌相关的免疫细胞组成及其在进展中的潜在作用的数据有限。我们通过根据导管原位癌亚型对免疫细胞亚群进行特征描述来研究与导管原位癌相关的免疫反应。根据 473 例患者的苏木精和伊红(H&E)染色切片评估导管原位癌相关肿瘤浸润淋巴细胞(TIL)密度。基于 ER、PR 和 HER2 对病例进行亚型分类。患者被分为 TIL 高或低。在整个切片上用 CD4、CD8、CD20、CD68、FOXP3 和 PD-L1(SP142 和 SP263)对 TIL 高病例的导管原位癌相关免疫细胞进行免疫染色。总共有 131/473 例患者(28.0%)被认为是 TIL 高。HER2+和三阴性导管原位癌中 TIL 高的病例百分比明显更高(P<0.0001)。总体而言,根据亚型免疫细胞组成没有统计学差异。然而,个别亚型比较显示,ER+HER2+病例的 CD8+T 细胞比例明显高于三阴性病例(P=0.047)。在 TIL 高的病例中,肿瘤细胞上 PD-L1-SP142 的表达与亚型相关(P=0.037);在 HER2+亚型中观察到的阳性病例数最少(与 ER 无关)。然而,在 TIL 高的导管原位癌中,两种克隆的 PD-L1 表达均有限。总之,在 HER+和三阴性导管原位癌中主要观察到大量的 TIL。与三阴性亚型相比,ER+HER2+亚型似乎吸引了更高比例的 CD8+T 细胞。在 TIL 高的病例中,HER2+亚组肿瘤细胞上的 PD-L1-SP142 表达最低。这表明 HER2+导管原位癌中存在更明显的抗肿瘤免疫,这可能与其生物学行为有关。